Although the small-sized albumin nanocomplexes (less than 10 nm) may be conducive to the tumor penetration after i.v. administration, nanocomplexes with such a small particle size showed insufficient circulation time in blood and poor tumor accumulation (Taguchi et al., 2012; Huo et al., 2017), resulting in a compromised therapeutic effect. The gene discussed is ALB; the disease is neoplasm.